OTCM
SHTDY
Market cap5.85bUSD
Oct 08, Last price
9.48USD
1D
0.64%
1Q
-10.99%
Jan 2017
-53.76%
IPO
-56.15%
Name
Sinopharm Group Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Sinopharm Group Co. Ltd., along with its affiliates, plays a significant role in the People's Republic of China's healthcare sector, primarily engaging in the wholesale and retail trade of pharmaceuticals, medical equipment, and health-related products. The company organizes its extensive operations across four distinct divisions. Its Pharmaceutical Distribution unit supplies a wide array of medicinal products to various clients, including hospitals, other distributors, retail pharmacies, and clinics. This segment also provides comprehensive distribution, logistics, and additional value-added services for both domestic and international pharmaceutical and healthcare product manufacturers and suppliers. The Medical Devices segment is dedicated to the distribution of medical equipment. Through its Retail Pharmacy division, the company oversees and franchises a substantial network of drugstores, which totaled 10,259 locations as of December 31, 2021. The Other Business segment is involved in the manufacturing and sale of pharmaceuticals, chemical reagents, and laboratory supplies. Beyond these core areas, the company's activities extend to property leasing and management; the trade of specialized medical instruments, traditional Chinese herbal medicines, antibiotics, and biological products; information technology development; a variety of consulting services (medicine, health, business, market information); investment management; import and export; and convention and exhibition services. Additionally, it manages medical project investments, consulting, and technology training initiatives. Sinopharm Group Co. Ltd. has formed a strategic partnership with I-Mab to enhance its commercial reach and market transformation efforts. The company was established in 2003, with its headquarters located in Shanghai, China, and operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.
Key people
Bin Jin
Non-Executive Chairman of the Board · since 2025
Non-Executive Vice Chairman of the Board · since 2014
Xiaojuan Li
Chief Financial Officer · since 2021
Maisong Cai
Vice President · since 2022
Zhanyu Chen
Vice President · since 2021
Yang Li
Vice President · since 2018
President, Executive Director · since 2024
Jinglin Sun
Executive Director · since 2025
Binghua Yang
Executive Director · since 2025
Yijian Wu
Company Secretary · since 2021
Yuqing Chen
Non-Executive Director · since 2025
Ligang Hu
Non-Executive Director · since 2025
Ying Li
Non-Executive Director · since 2025
Dongjiu Li
Non-Executive Director · since 2021
Yue Ma
Non-Executive Director · since 2025
Non-Executive Director · since 2017
Yonggang Xing
Non-Executive Director · since 2025
Jing Zu
Non-Executive Director · since 2025
Weiru Chen
Independent Non-Executive Director · since 2025
Independent Non-Executive Director · since 2018
IPO date
Sep 23, 2009
Employees
113,362
Domiciled in
CN
Incorporated in
CN
Legal address
Sinopharm Plaza, No. 1001 Zhongshan Road
Shanghai, SH 200051
CN
Shanghai, SH 200051
CN
Headquarters
Sinopharm Plaza, No. 1001 Zhongshan Road
Peking, SH 200051
CN
Peking, SH 200051
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||